immunoglobulin
fc
receptor
fcr
membran
molecul
express
sever
hematopoiet
cell
recogn
fc
region
sever
immunoglobulin
ig
class
subclass
distinguish
fcr
igg
ige
iga
igm
igaigm
sever
receptor
express
differ
cell
type
also
bind
ig
molecul
neonat
fcr
igg
fcrn
intestin
epithelium
placenta
endothelium
low
affin
b
cell
macrophag
polymer
ig
receptor
pigr
mucos
epithelium
function
antibodi
depend
one
hand
abil
recogn
antigen
epitop
hand
dynam
flexibl
capac
interact
cognat
fcr
engag
fcr
express
leukocyt
initi
number
proinflammatori
antiinflammatori
immun
modulatori
function
host
adapt
immun
respons
lead
protect
sometim
also
diseas
sever
fcr
requir
immunoreceptor
tyrosinebas
activ
motif
itam
sequenc
yxx
li
x
yxx
li
present
cytoplasm
tail
receptor
associ
subunit
chain
induc
cell
signal
itammedi
function
includ
phagocytosi
degranul
antibodydepend
cellular
cytotox
adcc
cytokin
lipid
mediat
superoxid
product
depend
cell
type
outsidein
signal
induc
ligand
engag
type
fcr
immun
complex
induc
receptor
aggreg
follow
activ
recruit
src
famili
kinas
sfk
lyn
fyn
former
induc
phosphoryl
conserv
tyrosin
itam
motif
follow
activ
recruit
tyrosin
kinas
syk
process
activ
variou
protein
involv
cell
respons
phospholipas
c
gamma
bruton
tyrosin
kinas
btk
guanin
nucleotid
exchang
factor
vav
phosphoinositid
hydrolysi
phosphatidylinositol
ptdin
gener
inositol
diacylglycerol
dag
lead
calcium
mobil
protein
kinas
c
pkc
activ
respect
calcium
influx
pkc
activ
promot
cell
respons
degranul
cytokin
product
vav
play
also
import
role
actin
cytoskeleton
remodel
control
phagocytosi
superoxid
product
nadph
oxidas
catalyz
phosphoryl
ptdin
ptdin
plasma
membran
pleckstrin
homolog
domain
contain
protein
protein
protein
kinas
b
pkbakt
btk
bind
ptdin
thu
recruit
inner
leaflet
plasma
membran
promot
phosphoryl
activ
figur
left
activ
itambear
immun
receptor
retrocontrol
itimbear
inhibitori
fcr
itim
motif
defin
singl
ivl
xyxx
lv
sequenc
howev
inhibit
cell
activ
motif
requir
colig
inhibitori
heterolog
activ
receptor
immun
complex
promot
recruit
inositol
phosphatas
figur
middl
anoth
inhibitori
mechan
recent
identifi
involv
itam
inde
follow
low
avid
ligand
interact
itambear
fcr
induc
sustain
inhibitori
signal
without
colig
heterolog
receptor
mechan
involv
mainten
immun
homeostasi
name
itammedi
inhibitori
signal
itami
shown
sever
low
affin
receptor
function
bifunct
receptor
induc
either
activ
inhibitori
signal
properti
exploit
reduc
suscept
autoimmun
inflammatori
diseas
monoval
dival
target
fcr
bear
itam
motif
induc
itami
signal
involv
activ
recruit
src
homolog
region
domaincontain
tyrosin
phosphatas
figur
right
demonstr
immunoreceptor
antigen
receptor
bcr
tcr
also
associ
upon
interact
low
avid
ligand
moreov
defici
hematopoiet
cell
favor
develop
variou
autoimmun
diseas
exampl
motheaten
mice
mevmev
express
approxim
wild
type
activ
develop
sever
immun
dysregul
autoantibodi
product
itami
signal
induc
fcr
lyn
essenti
phosphoryl
tyrosin
residu
activ
report
lyn
involv
posit
neg
signal
induc
antigen
receptor
lyn
play
import
role
neg
select
b
cell
bone
marrow
sinc
absenc
lyn
associ
decreas
b
cell
number
peripheri
mice
absenc
lyn
sfk
fyn
act
posit
regul
bcr
signal
suggest
loss
anergi
opposit
role
lyn
fyn
recent
demonstr
vivo
approach
lyn
defici
aggrav
autoinflammatori
diseas
nephriti
arthriti
absenc
fyn
protect
diseas
addit
show
activ
leukocyt
lupu
nephriti
patient
associ
fynactiv
signatur
suggest
balanc
lyn
fyn
dysregul
diseas
anoth
fcr
play
essenti
role
transcytosi
epitheli
cell
dimer
iga
also
pentamer
igm
notabl
iga
defici
call
polymer
immunoglobulin
receptor
pigr
pigr
intern
ligand
endocytosi
transcytos
basolater
membran
apic
side
epitheli
cell
central
role
receptor
gener
secretori
iga
form
iga
dimer
link
extracellular
domain
pigr
also
known
secretori
compon
exocrin
secret
establish
hostmicrobiota
symbiosi
mediat
protect
mucos
surfac
pathogen
fc
receptor
iga
igm
may
play
role
system
mucos
immun
shown
none
b
cell
cell
monocytemacrophag
nk
cell
human
blood
sampl
express
receptor
irrespect
age
ethnic
origin
gender
express
restrict
b
cell
germin
center
follicular
dendrit
cell
tonsillar
cell
although
exact
function
fulli
clarifi
may
play
import
role
antigen
present
b
cell
select
germin
center
respons
fcr
divid
type
type
ii
basi
conform
state
ig
fc
domain
interact
receptor
type
fc
receptor
interact
open
close
ig
fc
conform
figur
receptor
includ
contrast
type
ii
fcr
bind
preferenti
ig
fc
domain
close
conform
among
ctype
lectin
receptor
dcsign
figur
type
ii
fc
receptor
glycosyl
fc
domain
induc
conform
chang
occlud
bind
site
type
fc
receptor
lie
near
hing
region
open
conform
reveal
bind
site
domain
interfac
close
conform
receptor
bind
antibodi
two
receptorstoon
antibodi
stoichiometri
may
influenc
signal
initi
dcsign
exampl
bind
secretori
iga
play
intrigu
role
dendrit
cell
induc
tregmedi
toler
signal
receptor
howev
yet
document
compar
type
fcr
except
crosslink
b
cell
activ
camp
intracellular
calcium
flux
associ
activ
sfk
fyn
pathway
find
agreement
recent
data
type
fcr
indic
fyn
also
play
activ
role
b
cell
type
ii
fc
receptor
sever
singlenucleotid
polymorph
snp
report
gene
encod
activ
gene
encod
inhibitori
snp
describ
associ
autoimmun
diseas
sle
rheumatoid
arthriti
ra
addit
snp
copynumb
variat
cnv
gene
associ
suscept
autoimmun
disord
polymorph
concern
extracellular
domain
bind
igg
affect
affin
receptor
igg
subclass
howev
polymorph
cnv
clearli
identifi
studi
polymorph
one
second
iglik
extracellular
domain
result
point
mutat
amino
acid
posit
code
either
arginin
histidin
bind
less
effici
polymorph
describ
herit
risk
factor
autoimmun
infecti
diseas
moreov
genomewid
associ
studi
gwa
reveal
variant
associ
higher
suscept
develop
kawasaki
diseas
ulcer
coliti
variant
also
associ
syndrom
support
immun
complex
includ
autoantibodi
involv
inflammatori
respons
contrast
genotyp
homozyg
variantencod
gene
associ
sle
immun
thrombocytopen
purpura
itp
iga
nephropathi
igan
reveal
complex
contrast
pictur
role
immun
complex
autoimmun
diseas
regard
infecti
diseas
neutrophil
homozyg
gene
encod
variant
show
higher
capac
phagocytosi
homozyg
gene
encod
variant
agreement
patient
r
encod
allel
found
sever
case
sever
acut
respiratori
syndrom
infect
suscept
encapsul
microorgan
infect
attribut
poor
bind
variant
mice
express
homolog
transgen
mice
express
human
gene
encod
variant
develop
spontan
autoimmun
diseas
pneumon
glomerulonephr
ra
moreov
fact
express
background
mice
similarli
develop
thrombocytopenia
arthriti
indic
proautoimmun
signal
itam
suffici
induc
diseas
biochem
analys
show
two
tyrosin
itam
motif
need
induc
inflammatori
signal
taken
togeth
anim
model
underlin
critic
involv
polymorph
number
diseas
polymorph
found
inhibitori
gene
lead
singl
itot
amino
acid
substitut
transmembran
domain
residu
human
monocyt
express
fail
inhibit
heterolog
receptorsmedi
cell
activ
polymorph
associ
suscept
develop
autoimmun
diseas
sle
howev
discord
concern
snp
promot
region
haplotyp
haplotyp
variant
shown
snp
promot
haplotyp
upregul
express
neutrophil
monocyt
neg
correl
lupu
nephriti
agreement
previou
report
mous
slelik
model
suggest
express
protect
sle
howev
strike
contrast
appar
paradox
promot
haplotyp
found
author
correl
sle
posit
sle
vs
neg
lupu
nephriti
paradox
associ
promot
haplotyp
suggest
multifacet
impact
sle
may
depend
affect
cell
type
eg
monocyt
vs
neutrophil
altern
particular
cell
type
express
could
aggrav
protect
action
sle
depend
affect
tissu
cell
recruit
cell
impact
system
vs
local
aspect
diseas
thu
investig
necessari
elucid
associ
promot
haplotyp
diseas
develop
polymorph
character
point
mutat
codon
residu
encod
valin
phenylalanin
iglik
domain
near
membran
variant
higher
affin
human
igg
variant
associ
suscept
sle
crohn
diseas
diseas
although
studi
also
explor
associ
ra
v
f
variant
result
contradictori
question
remain
unsettl
sever
polymorph
found
includ
two
function
promot
region
encod
gene
rel
major
transcript
start
site
incid
polymorph
patient
igan
significantli
increas
compar
chronic
kidney
diseas
ckd
healthi
donor
hd
vs
ckd
vs
hd
polymorph
promot
region
appear
associ
suscept
igan
suggest
import
express
diseas
third
polymorph
describ
code
region
chang
codon
agc
ggc
lead
instead
cytoplasm
domain
receptor
interestingli
two
differ
allel
demonstr
significantli
differ
intracellular
activ
signal
proinflammatori
variant
associ
sle
two
ethnic
group
howev
polymorph
associ
autoimmun
diseas
system
sclerosi
ra
igan
fourth
polymorph
ag
nt
also
associ
aggress
periodont
patient
display
nt
aa
allel
present
polymorphonuclear
neutrophil
dysfunct
decreas
phagocytosi
periodontopath
bacteria
porphyromona
gingivali
compar
patient
express
nt
gg
regard
pigr
report
suscept
gene
nasopharyng
cancer
npc
associ
epsteinbarr
viru
ebv
lead
hypothesi
pigr
could
nasopharyng
epitheli
receptor
ebv
via
igaebv
complex
transcytosi
failur
due
missens
c
mutat
nucleotid
result
atov
mutat
near
endoproteolyt
cleavag
site
pigr
could
decreas
abil
pigr
releas
igaebv
complex
thu
increas
suscept
develop
npc
highaffin
express
mast
cell
basophil
play
import
role
allerg
diseas
sever
studi
identifi
two
polymorph
associ
allergi
c
andor
associ
atop
dermat
chronic
urticaria
asthma
high
serum
ige
level
polymorph
also
associ
allerg
inflammatori
diseas
atopi
nasal
allergi
tabl
summar
describ
fcr
allel
express
function
physiolog
patholog
sever
studi
highlight
alter
express
structur
function
patient
wherea
cell
healthi
donor
fail
express
signific
level
express
subpopul
cell
blood
sampl
patient
highli
enrich
induc
replicationcompet
provirus
suggest
hiv
reservoir
yet
studi
express
select
enrich
hiv
sivinfect
cell
peripher
blood
lymphoid
tissu
sinc
rest
cell
total
hiv
dna
amongst
cell
taken
togeth
wherea
express
cell
becom
marker
hiv
infect
involv
cell
aid
remain
elucid
inhibitori
contrast
downregul
autoimmun
diseas
notabl
memori
plasma
b
lymphocyt
activ
sle
patient
compar
healthi
individu
howev
downregul
seen
myeloidlineag
cell
also
observ
hashimoto
thyroid
high
level
express
monocyt
togeth
associ
proinflammatori
cytokin
profil
higher
potenc
antigen
present
allow
defin
monocyt
subset
distinct
phenotyp
function
express
dysregul
patient
aid
ankylos
spondyl
alcohol
liver
cirrhosi
henochschonlein
purpura
hsp
igan
studi
shown
biochem
abnorm
reveal
alter
protein
mobil
sdspage
suggest
alter
glycosyl
receptor
interestingli
mutat
studi
indic
residu
receptor
control
igabind
enhanc
parallel
abnorm
glycosyl
molecul
hypogalactosyl
hyposialyl
hing
region
observ
patient
igan
hsp
associ
shed
solubl
form
particip
format
circul
complex
complex
decreas
serum
igan
patient
sever
progress
diseas
compar
nonprogress
igan
patient
suggest
kidney
deposit
henc
possibl
nephrotox
action
complex
support
studi
igan
patient
recurr
diseas
kidney
transplant
studi
complex
decreas
serum
patient
recurr
igan
detect
kidney
mesangium
patient
recurr
diseas
direct
evid
nephrotox
role
complex
obtain
human
anim
model
experiment
studi
base
fact
mous
homolog
human
mice
express
human
human
spontan
develop
mesangi
deposit
complex
glomeruli
complex
captur
transferrin
receptor
upregul
mesangi
cell
interact
polymer
p
although
mechan
upregul
remain
poorli
understood
crosslink
enzym
transglutaminas
found
overexpress
associ
receptor
control
mesangi
complex
deposit
renal
injuri
polymer
induc
express
vitro
mesangi
cell
polymer
interact
trigger
activ
signal
mtor
erk
pathway
phosphoryl
erk
associ
diseas
progress
interestingli
enough
physiolog
interact
play
role
erythropoiesi
progress
igan
endstag
renal
diseas
may
also
involv
activ
tissu
macrophag
surround
hypogalactosyl
mesangi
lesion
inde
mice
rtol
substitut
posit
transmembran
region
develop
macrophag
infiltr
proteinuria
mutant
receptor
associ
itambear
signal
subunit
agreement
macrophag
express
wildtyp
express
abl
migrat
kidney
adopt
transfer
demonstr
chemotaxi
depend
subunit
note
found
associ
nonassoci
cell
sinc
mous
iga
human
interact
may
suffici
induc
receptor
shed
lead
iga
deposit
kidney
hypothes
receptor
type
could
cooper
induc
diseas
allow
iga
deposit
promot
inflammatori
cell
infiltr
diseas
progress
igm
receptor
defici
receptor
mice
reveal
receptor
play
crucial
role
b
cell
respons
mice
defici
fcmr
character
increas
preimmun
serum
igm
dysregul
humor
immun
respons
disturb
b
cell
subpopul
b
cell
prolifer
alter
bcr
ligat
autoantibodi
product
accordingli
chronic
lymphocyt
leukemia
cll
membran
express
solubl
form
serum
increas
potenti
mechan
propos
upregul
antigenindepend
selflig
bcr
cll
cell
induc
activ
syk
thu
increas
cell
surfac
express
furthermor
igm
antibodi
produc
cll
cell
differenti
plasma
cell
recogn
solubl
lymphocyt
membran
selfantigen
igmselfantigen
immun
complex
would
crosslink
bcr
favor
cell
surviv
altern
splice
variant
solubl
increas
cll
patient
biolog
function
unclear
type
ii
fcr
increas
express
monocyt
aid
patient
associ
aberr
activ
phenotyp
cell
immunopathogenesi
aid
interestingli
despit
known
abil
downregul
monocyt
express
aid
environ
associ
suppress
express
monocyt
indic
impair
neg
regul
patient
bcll
also
patient
strongli
express
associ
b
cell
activ
prolifer
moreov
alter
phosphoryl
intracellular
tail
report
bcll
b
lymphocyt
support
activ
role
diseas
murin
model
studi
patient
suggest
major
role
activ
fcr
initi
propel
immun
complexmedi
inflammatori
reaction
exampl
human
transgen
mice
hypersensit
pathogen
antibodi
develop
destruct
arthrit
syndrom
ex
vivo
experiment
circul
monocyt
ra
patient
suggest
respons
product
reactiv
oxygen
speci
antireceptor
monoclon
antibodi
intact
antibodi
antibodi
fragment
well
varieti
small
molecul
design
interact
igbind
domain
activ
fcr
approach
shown
encourag
result
test
vitro
vivo
block
immun
complexmedi
cell
effect
inflamm
recent
demonstr
dival
target
f
ab
fragment
amelior
raassoci
inflamm
therapeut
effect
mediat
induct
inhibitori
itam
itami
signal
activ
moreov
treatment
inflammatori
synovi
cell
ra
patient
f
fragment
antibodi
inhibit
product
reactiv
oxygen
speci
associ
induct
itami
signal
data
suggest
target
specif
antibodi
clone
mab
could
amelior
raassoci
inflamm
fab
f
ab
fragment
also
demonstr
effici
ra
interestingli
autoimmun
blister
skin
diseas
involv
interact
iga
autoantibodi
neutrophil
target
block
peptid
antibodi
prevent
neutrophil
migrat
tissu
damag
exvivo
allergi
treatment
antiig
antibodi
consid
therapeut
option
long
time
recombin
antiig
human
monoclon
name
omalizumab
use
sever
clinic
trial
show
efficaci
igemedi
allerg
reaction
inhibit
ige
bind
surfac
mast
cell
basophil
abovedescrib
upregul
express
cll
cell
signific
clinic
interest
easili
evalu
flow
cytometri
cell
addit
level
solubl
may
correl
diseas
progress
thu
may
use
new
biomark
cll
good
target
also
involv
pathogenesi
cll
progress
diseas
support
leukem
cell
surviv
henc
disrupt
cll
surviv
signal
might
achiev
therapeut
target
howev
larg
cohort
cll
patient
requir
valid
two
applic
intraven
immunoglobulin
ivig
harvest
pool
plasma
healthi
donor
consist
igg
subclass
distribut
correspond
found
normal
human
serum
ivig
use
treatment
sever
immunodefici
diseas
includ
idiopath
thrombocytopen
purpura
itp
kawasaki
diseas
neurolog
diseas
syndrom
chronic
inflammatori
demyelin
polyneuropathi
myasthenia
gravi
sclerosi
autoimmun
enceph
itp
patient
administr
ivig
effici
attenu
platelet
clearanc
circul
first
propos
mechan
competit
blockag
activ
myeloid
cell
ivig
turn
decreas
autoantibodymedi
platelet
phagocytosi
adcc
platelet
furthermor
pediatr
itp
patient
intraven
administr
fragment
prepar
ivig
result
rapid
recoveri
platelet
count
indic
role
ivig
action
anoth
ivig
antiinflammatori
mechan
involv
satur
fcrn
igg
recycl
receptor
fcrn
play
import
role
mainten
igg
halflif
therefor
inhibit
autoantibodi
activ
induc
alter
interact
fcrn
impair
halflif
acceler
clear
circul
ivig
compet
autoantibodi
fcrn
bind
could
therefor
facilit
clear
role
inhibitori
propos
exclus
ivig
action
explain
fc
depend
effect
statement
base
notabl
studi
show
decreas
antiinflammatori
effect
ivig
anim
studi
role
ivigmedi
inhibit
report
although
mechan
action
clearli
establish
recent
report
ivig
control
inflammatori
respons
itami
signal
data
base
vitro
target
ivig
physiolog
concentr
igg
show
inhibitori
effect
endocytosi
confirm
target
f
fragment
specif
antibodi
result
support
vivo
mice
target
receptor
ivig
specif
antibodi
inhibitori
effect
abolish
receptordefici
mice
therefor
ivig
could
use
combin
nonexclus
mechan
promot
protect
autoimmun
diseas
although
ivig
well
toler
patient
develop
immedi
delay
advers
effect
depend
time
occurr
flulik
symptom
fever
fatigu
nausea
frequent
advers
effect
delay
advers
effect
frequent
thrombot
event
neurolog
disord
renal
failur
delay
advers
effect
rare
danger
major
advers
effect
associ
high
dose
immunoglobulin
thu
determin
individu
dosag
guarante
efficaci
therapi
minim
advers
effect
urgent
goal
treatment
highli
purifi
serum
monomer
iga
miga
decreas
cell
activ
itami
signal
human
miga
fab
fragment
use
prevent
treat
collagen
antibodyinduc
arthriti
mice
miga
treatment
decreas
significantli
leukocyt
infiltr
inflam
joint
mice
associ
phosphoryl
residu
joint
tissu
cell
moreov
miga
revers
activ
itam
itami
signatur
state
inflamm
synovi
fluid
isol
ra
patient
note
protect
also
achiev
human
serum
iga
find
open
new
avenu
develop
concept
iviga
new
treatment
option
inflammatori
autoimmun
diseas
fcr
contain
inhibitori
itim
motif
serv
critic
neg
regul
immun
complex
driven
reaction
mice
lack
autoimmun
symptom
exacerb
partial
restor
express
b
cell
rescu
mice
develop
slelik
phenotyp
sever
specif
mab
develop
one
chimer
human
direct
myeloidcytotox
b
cell
antibodi
potenti
serv
novel
immun
suppressor
autoimmun
either
block
b
cell
activ
target
destruct
addit
may
advantag
antibodi
abil
target
plasma
cell
block
fcrnigg
interact
decreas
circul
igg
level
one
strategi
treat
autoimmun
diseas
absenc
interact
fcrn
igg
would
degrad
lysosom
quickli
instead
recycl
back
circul
one
straightforward
method
would
use
recombin
solubl
human
fcrn
compet
membran
fcrn
igg
anoth
approach
block
iggfcrn
bind
would
engin
bait
igg
occupi
fcrn
thu
prevent
bind
endogen
igg
bait
antibodi
gener
much
higher
affin
fcrn
acid
neutral
ph
therebi
provid
effect
occup
fcrn
compet
result
degrad
endogen
igg
antibodi
also
call
abdeg
antibodi
enhanc
igg
degrad
fcrnspecif
block
mab
would
also
provid
interfer
fcrnigg
interact
one
mab
examin
rat
passiv
activ
model
myasthenia
gravi
prototyp
antibodymedi
autoimmun
diseas
treatment
mab
result
amelior
diseas
symptom
dosedepend
manner
togeth
greatli
reduc
level
pathogen
antibodi
serum
target
fcr
monomer
immunoglobulin
f
fragment
specif
antibodi
induc
itami
signal
involv
recruit
lyn
fyn
src
kinas
lyn
lead
partial
phosphoryl
itam
motif
tyrosin
residu
conform
chang
allow
recruit
domain
itam
phosphotyrosin
residu
recruit
induc
lyndepend
phosphoryl
phosphatas
activ
inhibit
recruit
variou
protein
induc
heterolog
receptor
contrast
multival
crosslink
immunoreceptor
immun
complex
induc
recruit
src
kinas
lyn
fyn
receptor
lead
full
phosphoryl
tyrosin
residu
present
itam
motif
lead
activ
recruit
kinas
syk
parallel
fyn
initi
signal
pathway
involv
axi
lead
inactiv
phosphoryl
residu
bar
recruit
plasma
membran
sinc
phosphoryl
keep
phosphatas
close
conform
recent
studi
show
phosphoryl
residu
fyn
axi
render
residu
inaccess
lyn
agreement
absenc
fyn
favor
phosphoryl
lyn
despit
crosslink
result
suggest
select
absenc
inhibit
fyn
may
abolish
inflamm
autoimmun
proinflammatori
diseas
taken
togeth
inhibit
fyn
molecul
upstream
downstream
sfk
revers
inflamm
autoimmun
inflammatori
diseas
thu
could
new
therapeut
strategi
decreas
activ
itam
signal
diseas
along
line
inhibit
major
player
axi
prevent
ra
lupu
nephriti
progress
mous
model
howev
mention
sinc
fyn
essenti
activ
itam
signal
ie
phagocytosi
inhibit
sfk
may
favor
infect
moreov
fyn
play
also
role
independ
fcr
shown
absenc
fyn
impair
multipolarbipolar
transit
newli
gener
neuron
neurit
format
earli
phase
migrat
addit
inhibit
fyn
decreas
branch
number
migrat
cortic
neuron
anoth
import
hurdl
lyn
fyn
present
high
homolog
current
select
inhibitori
drug
therefor
fyn
appear
best
target
treat
autoimmun
proinflammatori
diseas
identif
new
target
downstream
fyn
express
specif
immun
cell
involv
autoimmun
diseas
permit
develop
new
therapeut
strategi
autoimmun
diseas
involv
fcr
fc
receptor
may
respons
diseas
dysregul
spite
physiolog
protect
function
unravel
aspect
express
function
regul
fcr
biolog
help
defin
approach
correct
first
wield
second
restor
homeostasi
thu
repres
new
hope
innov
antiinflammatori
strategi
progress
two
aspect
current
well
underway
alreadi
propos
new
potent
therapeut
tool
futur
field
promis
scientif
excit
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
